Employees Retirement System of Texas Acquires New Stake in Genmab A/S (NASDAQ:GMAB)

Employees Retirement System of Texas bought a new stake in Genmab A/S (NASDAQ:GMAB) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 78,950 shares of the company’s stock, valued at approximately $16,477,000.

Several other hedge funds also recently modified their holdings of GMAB. Charles Schwab Investment Management Inc. boosted its position in Genmab A/S by 94.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after acquiring an additional 12,654 shares during the last quarter. AIMZ Investment Advisors LLC purchased a new stake in shares of Genmab A/S in the fourth quarter valued at $3,525,000. HighTower Advisors LLC acquired a new position in Genmab A/S in the third quarter valued at $273,000. Verition Fund Management LLC purchased a new position in Genmab A/S during the third quarter worth about $709,000. Finally, FMR LLC boosted its stake in Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Truist Financial dropped their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Sanford C. Bernstein downgraded Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. Finally, William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.33.

Genmab A/S Stock Down 4.4 %

NASDAQ GMAB opened at $18.39 on Monday. The stock has a market cap of $12.17 billion, a PE ratio of 10.57, a P/E/G ratio of 2.65 and a beta of 1.07. The business has a 50 day moving average price of $20.67 and a two-hundred day moving average price of $21.57. Genmab A/S has a fifty-two week low of $17.63 and a fifty-two week high of $30.41.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Sell-side analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.